Meeting
2024 ASCO Genitourinary Cancers Symposium
An observational multicenter French study on unanswered questions in patients with advanced renal cell carcinoma (aRCC) treated with cabozantinib: OCTOPUS.
Presenter
Constance Thibault, MD
Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 430)
DOI
10.1200/JCO.2024.42.4_suppl.430
Abstract #
430
Poster Bd #
H12
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2023 ASCO Genitourinary Cancers Symposium
CaboPoint: Interim results from a phase 2 study of cabozantinib after checkpoint inhibitor (CPI) therapy in patients with advanced renal cell carcinoma (RCC).
Speaker: Laurence Albiges, MD, PhD
Videos & Slides
2023 ASCO Genitourinary Cancers Symposium
CaboPoint: Interim results from a phase 2 study of cabozantinib after checkpoint inhibitor (CPI) therapy in patients with advanced renal cell carcinoma (RCC).
Speaker: Laurence Albiges, MD, PhD
Videos & Slides
2021 ASCO Annual Meeting
A phase 2 single-arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune checkpoint inhibitor: The BREAKPOINT trial (MeetUro trial 03-NCT03463681).
Speaker: Giuseppe Procopio, MD
Videos & Slides
2021 ASCO Annual Meeting
Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) (CaNI) for advanced renal cell carcinoma with variant histology (aRCCVH).
Speaker: Bradley Alexander McGregor, MD